These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24773792)

  • 1. Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.
    Goldstein RC; Husk G; Jodlowski T; Mildvan D; Perlman DC; Ruhe JJ
    Am J Infect Control; 2014 May; 42(5):539-41. PubMed ID: 24773792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
    Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
    Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
    Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
    Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.
    Dean NC; Sperry P; Wikler M; Suchyta MS; Hadlock C
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1164-9. PubMed ID: 16569825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
    Katz E; Larsen LS; Fogarty CM; Hamed K; Song J; Choudhri S
    J Emerg Med; 2004 Nov; 27(4):395-405. PubMed ID: 15498622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia?
    Sánchez F; Mensa J; Martínez JA; García E; Marco F; González J; Marcos MA; Soriano A; Torres A
    Clin Infect Dis; 2003 May; 36(10):1239-45. PubMed ID: 12746768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
    Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
    Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stratifying risk factors for multidrug-resistant pathogens in hospitalized patients coming from the community with pneumonia.
    Aliberti S; Di Pasquale M; Zanaboni AM; Cosentini R; Brambilla AM; Seghezzi S; Tarsia P; Mantero M; Blasi F
    Clin Infect Dis; 2012 Feb; 54(4):470-8. PubMed ID: 22109954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy.
    Maruyama T; Fujisawa T; Okuno M; Toyoshima H; Tsutsui K; Maeda H; Yuda H; Yoshida M; Kobayashi H; Taguchi O; Gabazza EC; Takei Y; Miyashita N; Ihara T; Brito V; Niederman MS
    Clin Infect Dis; 2013 Nov; 57(10):1373-83. PubMed ID: 23999080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceftaroline fosamil for treatment of community-acquired pneumonia: findings from FOCUS 1 and 2 and potential role in therapy.
    DiMondi VP; Drew RH; Chen LF
    Expert Rev Anti Infect Ther; 2011 Aug; 9(8):567-72. PubMed ID: 21819323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia.
    Rahav G; Fidel J; Gibor Y; Shapiro M
    Int J Antimicrob Agents; 2004 Aug; 24(2):181-4. PubMed ID: 15288319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
    Mortensen EM; Restrepo MI; Anzueto A; Pugh J
    Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
    Samsa GP; Matchar DB; Harnett J; Wilson J
    Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is gentamicin safe and effective for severe community-acquired pneumonia? An 8-year retrospective cohort study.
    Brereton CJ; Lennon D; Browning S; Dunn E; Ferguson JK; Davis JS
    Int J Antimicrob Agents; 2018 Jun; 51(6):862-866. PubMed ID: 29410326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia.
    Lodise TP; Kwa A; Cosler L; Gupta R; Smith RP
    Antimicrob Agents Chemother; 2007 Nov; 51(11):3977-82. PubMed ID: 17709460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital.
    Feldman RB; Rhew DC; Wong JY; Charles RA; Goetz MB;
    Arch Intern Med; 2003 Jul; 163(14):1718-26. PubMed ID: 12885688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ertapenem as initial antimicrobial monotherapy for patients with chronic obstructive pulmonary disease hospitalized with typical community-acquired pneumonia.
    Friedland IR; McCarroll KA; DiNubile MJ; Woods GL
    Pulm Pharmacol Ther; 2004; 17(4):199-203. PubMed ID: 15219264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implementation of an inpatient management and discharge strategy for patients with community-acquired pneumonia.
    Stone RA; Mor MK; Lave JR; Hough LJ; Fine MJ
    Am J Manag Care; 2005 Aug; 11(8):491-9. PubMed ID: 16095435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.